Compare Logitech International SA (LOGI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Novavax Inc — how do they compare? Logitech International SA trades at $98.15 (market cap $14.46B), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Logitech International SA is far larger — about 7.9× Novavax Inc's market cap, and Logitech International SA pays a 1.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Novavax Inc for 59 Days on average.
| LOGI | NVAX | |
|---|---|---|
Market Cap | $14.46B | $1.82B |
Volume | 349,547 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $126.69 | $12.56 |
52-Week Low | $85.84 | $6.22 |
Typical Hold Time | 92 Days | 59 Days |
Enterprise Value | $12.79B | $1.39B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $98.27, down 3.83% over the past day, amid a neutral technical backdrop. The stock shows strong fundamental health with consistent earnings beats, a robust net income margin of 16.28%, and a forward P/E of 18.64. Recent product launches, including the Zone Vibe Pro headset and MX Keypad, highlight innovation in the hybrid work and gaming segments. Cash flow trends are positive, with 2026 operating cash flow projected at $1.1 billion, supporting dividend payments and growth initiatives.
The investment outlook is balanced. Upside is supported by solid profitability, strategic partnerships like the SEGA alliance, and analyst consensus target of $107. However, risks include competitive pressures in peripherals, sensitivity to consumer spending, and the stock's high P/B ratio of 6.18. Investor sentiment is mixed, with technical indicators neutral and analyst ratings evenly split between buy, hold, and sell.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
